FMP
Cardiff Oncology, Inc.
CRDF
NASDAQ
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
4.35 USD
-0.02 (-0.46%)
About
ceo
Dr. Mark Erlander Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.cardiffoncology.com
exchange
NASDAQ
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, ...
CIK
0001213037
ISIN
US14147L1089
CUSIP
14147L108
Address
11055 Flintkote Avenue
Phone
858 952 7570
Country
US
Employee
31
IPO Date
Jul 27, 2004
Summary
CIK
0001213037
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
14147L108
ISIN
US14147L1089
Country
US
Price
4.35
Beta
1.97
Volume Avg.
1.83M
Market Cap
194.35M
Shares
-
52-Week
0.94-6.42
DCF
0.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.68
P/B
-
Website
https://www.cardiffoncology.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CRDF News
It looks like there's no news available.
